REVTORPYK™ (gedatolisib) Included in NCCN Clinical Practice Guidelines for HR+/HER2- Breast Cancer

Celcuity Inc. announced that REVTORPYK™ (gedatolisib), a recently FDA-approved treatment for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, has been recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology as a preferred Category 1 second-line and/or subsequent-line therapy. This inclusion highlights the clinical relevance of the treatment option for patients.